Yuhan said on the 14th that it will receive a $30 million (44.8 billion won) milestone payment for the lung cancer drug Leclaza from Janssen Biotech. Yuhan transferred Leclaza to Janssen Biotech, a subsidiary of Johnson & Johnson, in 2018.
Yuhan's revenue includes a $50 million (74.6 billion won) upfront payment, milestone payments received upon reaching certain stages, and royalties based on sales. Including the upfront and milestones, Yuhan is set to receive $950 million (1.42 trillion won).
Leclaza can be used in combination with Janssen Biotech's Amivantamab. Yuhan received this milestone as Leclaza was commercialized in Europe. Cumulative milestones total $300 million (448 billion won), equivalent to one-third of the total amount to be received.
Leclaza, in 2024, became the first domestically developed anticancer drug to win approval from the U.S. Food and Drug Administration (FDA) and has entered Europe, Asia, and Oceania. A company official said, "Royalties are expected to increase in line with global sales."